Reyataz (atazanavir) used in combination with ritonavir wins FDA approval for treatment of HIV-1 patients.
The U.S. Food and Drug Administration has approved the use of Reyataz (atazanavir) 300 mg once daily with ritonavir 100 mg as part of combination therapy in previously untreated HIV-1 infected patients.
Reyataz is a prescription medicine used in combination with other medicines to treat people with the HIV virus. "Bristol-Meyers Squibb is committed to developing medicines that enhance the care of people living with HIV and AIDS," Elliot Sigal, a executive vice president of Bristol-Meyers, the maker of the drug, said. "Boosted Reyataz provides healthcare professionals with a newly-approved, once-daily dosing option as part of [combo] therapy."